同源康医药-B(02410)

10.370-0.430-3.98%

社区社区
资讯资讯
资料资料
公告公告

- 最新
- 推荐
公司概况
公司名称
同源康医药-B
所属市场
SEHK
成立日期
- -
员工人数
- -
办公地址
- -
公司网址
- -
邮政编码
- -
联系电话
- -
联系传真
- -
公司概况
浙江同源康医药股份有限公司是一家致力于开发及商业化医药产品的中国公司。该公司专注于小分子药物开发，其主要产品包括TY-9591、TY-302和TY-2136。TY-9591是一种第三代EGFR-TKI，对EGFR突变具有抗肿瘤作用。TY-302是一种为治疗乳腺癌及前列腺癌等晚期实体瘤而开发的强效、选择性口服CDK4/6抑制剂。TY-2136b为自主研发、口服ROS1/NTRK抑制剂，用于治疗实体瘤。
- 2025-09-19
  半年度报告
  2025中期报告
  2025中期报告
- 2025-08-31
  须予披露的交易
  须予披露交易 - 认购理财产品；投资及赎回基金权益；及更新全球发售闲置资金用途
  须予披露交易 - 认购理财产品；投资及赎回基金权益；及更新全球发售闲置资金用途
- 2025-08-31
  半年度报告
  截至2025年6月30日止六个月中期业绩公告；非执行董事辞任；及建议修订组织章程细则
  截至2025年6月30日止六个月中期业绩公告；非执行董事辞任；及建议修订组织章程细则
- 2025-08-04
  股份发行
  完成根据一般授权配售新H股
  完成根据一般授权配售新H股
- 2025-07-29
  股份发行
  根据一般授权配售新H股
  根据一般授权配售新H股
- 2025-04-29
  年度报告
  2024年度报告
  2024年度报告
- 2025-03-27
  年度报告
  截至2024年12月31日止年度年度业绩公告；非执行董事辞任；及建议修订组织章程细则
  截至2024年12月31日止年度年度业绩公告；非执行董事辞任；及建议修订组织章程细则
- 2024-09-27
  半年度报告
  2024中期报告
  2024中期报告
- 2024-08-30
  半年度报告
  截至2024年6月30日止六个月中期业绩公告
  截至2024年6月30日止六个月中期业绩公告
- 2024-08-12
  股份发售
  全球发售
  全球发售

分时
5日
日
周
月

数据加载中...

最高

10.780

今开

10.700

量比

3.23

最低

9.850

昨收

10.800

换手率

1.63%

热议股票

{"pagemeta":{"title":"同源康医药-B(02410)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供同源康医药-B(02410)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"同源康医药-B,02410,同源康医药-B股票,同源康医药-B股票老虎,同源康医药-B股票老虎国际,同源康医药-B行情,同源康医药-B股票行情,同源康医药-B股价,同源康医药-B股市,同源康医药-B股票价格,同源康医药-B股票交易,同源康医药-B股票购买,同源康医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"同源康医药-B(02410)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供同源康医药-B(02410)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}},"tab":"community","symbol":"02410","data":{"stockData":{"symbol":"02410","market":"HK","secType":"STK","nameCN":"同源康医药-B","latestPrice":10.37,"timestamp":1772611696006,"preClose":10.8,"halted":0,"volume":6127187,"delay":0,"changeRate":-0.03981481481481495,"floatShares":375457818,"shares":380065818,"eps":-1.2982564541859447,"marketStatus":"已收盘","change":-0.43,"latestTime":"03-04 16:08:16","open":10.7,"high":10.78,"low":9.85,"amount":62320919,"amplitude":0.086111,"askPrice":10.38,"askSize":1000,"bidPrice":10.37,"bidSize":5000,"shortable":3,"etf":0,"ttmEps":-0.8743172547674127,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772674200000},"marketStatusCode":5,"adr":0,"listingDate":1724083200000,"exchange":"SEHK","adjPreClose":10.8,"openAndCloseTimeList":[[1772587800000,1772596800000],[1772600400000,1772611200000]],"volumeRatio":3.230272,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"tweetData":{"bottom":false,"list":[{"cardType":"TWEET","cardId":"TWEET.539102768996368","cardData":[{"tweetId":"539102768996368","author":{"authorId":"4204683525604390","idStr":"4204683525604390","name":"龙龙行天下","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":9,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 还好下午收盘价回到了10块以上，结构暂时没有走坏","plainDigest":"$同源康医药-B(02410)$ 还好下午收盘价回到了10块以上，结构暂时没有走坏","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1772637755372,"gmtModify":1772637757288,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":0,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/539102768996368","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":66,"displayRows":4,"foldSize":0,"authorId":"4204683525604390"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.538575840474688","cardData":[{"tweetId":"538575840474688","author":{"authorId":"4203843771083212","idStr":"4203843771083212","name":"乐山大佛笑哈哈","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 股价的短期整理和市值压力，并未改变市场对其核心产品TY-9591作为潜在“first-in-class”脑转移肺癌治疗药物的长期价值判断","plainDigest":"$同源康医药-B(02410)$ 股价的短期整理和市值压力，并未改变市场对其核心产品TY-9591作为潜在“first-in-class”脑转移肺癌治疗药物的长期价值判断","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1772507328745,"gmtModify":1772507330698,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":30,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/538575840474688","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":133,"displayRows":4,"foldSize":0,"authorId":"4203843771083212"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.538376038315504","cardData":[{"tweetId":"538376038315504","author":{"authorId":"3476670504434547","idStr":"3476670504434547","name":"木下上山虎","avatar":"https://static.laohu8.com/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":34,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ &nbsp;</a>同源康小幅震荡一下，涨一天跌一天，保持耐心就行","plainDigest":"$同源康医药-B(02410)$ 同源康小幅震荡一下，涨一天跌一天，保持耐心就行","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1772460385345,"gmtModify":1772460387423,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":105,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/538376038315504","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":65,"displayRows":4,"foldSize":0,"authorId":"3476670504434547"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.537162962563912","cardData":[{"tweetId":"537162962563912","author":{"authorId":"4193625296607780","idStr":"4193625296607780","name":"打铁不如李铁","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 根据法规，纳入优先审评的NDA审评时限有望缩短，市场普遍预期若进展顺利，TY-9591有望在2026年内获得上市批准","plainDigest":"$同源康医药-B(02410)$ 根据法规，纳入优先审评的NDA审评时限有望缩短，市场普遍预期若进展顺利，TY-9591有望在2026年内获得上市批准","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1772164186755,"gmtModify":1772164188673,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":184,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/537162962563912","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":120,"displayRows":4,"foldSize":0,"authorId":"4193625296607780"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.536987331838000","cardData":[{"tweetId":"536987331838000","author":{"authorId":"4218001298160580","idStr":"4218001298160580","name":"G股叶荣添","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 同源康近期交易相对缩量，等着新的利好才能启动吗","plainDigest":"$同源康医药-B(02410)$ 同源康近期交易相对缩量，等着新的利好才能启动吗","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1772121391803,"gmtModify":1772121393889,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":48,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/536987331838000","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":66,"displayRows":4,"foldSize":0,"authorId":"4218001298160580"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.536525771838320","cardData":[{"tweetId":"536525771838320","author":{"authorId":"4203843771083212","idStr":"4203843771083212","name":"乐山大佛笑哈哈","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 被调入指数通常意味着公司符合一定的流动性、市值等标准，能提升在机构投资者中的知名度，为股价带来长期支撑","plainDigest":"$同源康医药-B(02410)$ 被调入指数通常意味着公司符合一定的流动性、市值等标准，能提升在机构投资者中的知名度，为股价带来长期支撑","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1772008622738,"gmtModify":1772008625036,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":142,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/536525771838320","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":120,"displayRows":4,"foldSize":0,"authorId":"4203843771083212"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.536265888621448","cardData":[{"tweetId":"536265888621448","author":{"authorId":"4214049281636630","idStr":"4214049281636630","name":"永远的话事人","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":7,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 创新药最近表现都比较低迷，只能保持持仓耐心才行","plainDigest":"$同源康医药-B(02410)$ 创新药最近表现都比较低迷，只能保持持仓耐心才行","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1771945175066,"gmtModify":1771945176917,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":145,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/536265888621448","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":66,"displayRows":4,"foldSize":0,"authorId":"4214049281636630"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.535816462697528","cardData":[{"tweetId":"535816462697528","author":{"authorId":"4203909980173582","idStr":"4203909980173582","name":"Y2301156","avatar":"https://static.tigerbbs.com/cba88a66df5e28ed78bd3f5925c72e69","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":3,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 被调入相关指数，此举有望在未来吸引部分被动型指数基金的配置资金","plainDigest":"$同源康医药-B(02410)$ 被调入相关指数，此举有望在未来吸引部分被动型指数基金的配置资金","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1771835543106,"gmtModify":1771835544834,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":218,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/535816462697528","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":82,"displayRows":4,"foldSize":0,"authorId":"4203909980173582"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.532216637818560","cardData":[{"tweetId":"532216637818560","author":{"authorId":"4193625296607780","idStr":"4193625296607780","name":"打铁不如李铁","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 公司已与国内TOP10肿瘤医院建立临床推广合作意向，与国药控股、华润医药等达成初步配送协议，商业化网络布局提前完成","plainDigest":"$同源康医药-B(02410)$ 公司已与国内TOP10肿瘤医院建立临床推广合作意向，与国药控股、华润医药等达成初步配送协议，商业化网络布局提前完成","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1770954823900,"gmtModify":1770954826103,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":440,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/532216637818560","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":127,"displayRows":4,"foldSize":0,"authorId":"4193625296607780"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.532018657756672","cardData":[{"tweetId":"532018657756672","author":{"authorId":"4136460772891970","idStr":"4136460772891970","name":"牛熊两吃","avatar":"https://static.laohu8.com/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":12,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$</a> 短期就是这样的行情，尤其考虑下周进入春节假期，估计不会有太大波动","plainDigest":"$同源康医药-B(02410)$ 短期就是这样的行情，尤其考虑下周进入春节假期，估计不会有太大波动","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1770906453278,"gmtModify":1770906455600,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":542,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/532018657756672","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":83,"displayRows":4,"foldSize":0,"authorId":"4136460772891970"}],"position":0}],"size":10},"newsData":null,"noticeData":{"listData":[{"cdn_pdf":true,"hasAttachments":false,"id":"20185733","market":"hk","labels":[],"media":"港交所","original_id":"N.HK529G9em8zu","pdf_url":"https://static.tigerbbs.com/baba20cef37d43d9a1b4365303cad8db","pub_time":1758270720000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"2025中期报告","symbol":"02410","title":"2025中期报告","titleType":"半年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0919/2025091900443_c.pdf","us_notice_code":"财务报表/环境、社会及管治资料 - [中期/半年度报告]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Interim Report","event_type":"important_notice","event_name":"半年度报告","pubTime":"2025-09-19 16:32","pubTimestamp":1758270720,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"20112040","market":"hk","labels":[],"media":"港交所","original_id":"N.HKEBcbBF6ATz","pdf_url":"https://static.tigerbbs.com/375db4bf747e4d53a101c0ea7e90805f","pub_time":1756636620000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"须予披露交易 - 认购理财产品；投资及赎回基金权益；及更新全球发售闲置资金用途","symbol":"02410","title":"须予披露交易 - 认购理财产品；投资及赎回基金权益；及更新全球发售闲置资金用途","titleType":"须予披露的交易","type":"hkTrade","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0831/2025083100074_c.pdf","us_notice_code":"公告及通告 - [须予披露的交易 / 其他-杂项]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"交易相关","type_name_en":"Transaction Related","titleTypeEn":"","event_type":"important_notice","event_name":"须予披露的交易","pubTime":"2025-08-31 18:37","pubTimestamp":1756636620,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"20112037","market":"hk","labels":[],"media":"港交所","original_id":"N.HK9qKjV1tTLN","pdf_url":"https://static.tigerbbs.com/23daaef8e7404155822c39fdfb71940a","pub_time":1756636200000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"截至2025年6月30日止六个月中期业绩公告；非执行董事辞任；及建议修订组织章程细则","symbol":"02410","title":"截至2025年6月30日止六个月中期业绩公告；非执行董事辞任；及建议修订组织章程细则","titleType":"半年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0831/2025083100066_c.pdf","us_notice_code":"公告及通告 - [中期业绩 / 修订宪章文件 / 更换董事或重要行政职能或职责的变更]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Interim Report","event_type":"important_notice","event_name":"半年度报告","pubTime":"2025-08-31 18:30","pubTimestamp":1756636200,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"19944295","market":"hk","labels":[],"media":"港交所","original_id":"N.HKBjBpozdtEZ","pdf_url":"https://static.tigerbbs.com/34fc3516e01d405f8935b05e06943126","pub_time":1754318520000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"完成根据一般授权配售新H股","symbol":"02410","title":"完成根据一般授权配售新H股","titleType":"股份发行","type":"hkShares","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0804/2025080402347_c.pdf","us_notice_code":"公告及通告 - [配售 / 根据一般性授权发行股份]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"股权股本","type_name_en":"Equity Change","titleTypeEn":"Share Issuance","event_type":"important_notice","event_name":"股份发行","pubTime":"2025-08-04 22:42","pubTimestamp":1754318520,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"19918222","market":"hk","labels":[],"media":"港交所","original_id":"N.HK5XNhTGVFfY","pdf_url":"https://static.tigerbbs.com/ca188062973d42f3b71aee148112a82b","pub_time":1753740420000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"根据一般授权配售新H股","symbol":"02410","title":"根据一般授权配售新H股","titleType":"股份发行","type":"hkShares","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0729/2025072900004_c.pdf","us_notice_code":"公告及通告 - [配售 / 根据一般性授权发行股份]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"股权股本","type_name_en":"Equity Change","titleTypeEn":"Share Issuance","event_type":"important_notice","event_name":"股份发行","pubTime":"2025-07-29 06:07","pubTimestamp":1753740420,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"19562509","market":"hk","labels":[],"media":"港交所","original_id":"N.HK6jhALatDTA","pdf_url":"https://static.tigerbbs.com/3655ef960b914b0888916cb27a57c97b","pub_time":1745916120000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"2024年度报告","symbol":"02410","title":"2024年度报告","titleType":"年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0429/2025042901084_c.pdf","us_notice_code":"财务报表/环境、社会及管治资料 - [年报 / 环境、社会及管治资料/报告]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Annual Report","event_type":"important_notice","event_name":"年度报告","pubTime":"2025-04-29 16:42","pubTimestamp":1745916120,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"19298545","market":"hk","labels":[],"media":"港交所","original_id":"N.HK5kKrBbdctD","pdf_url":"https://static.tigerbbs.com/718c98826c324bf0b2e29802f28dd06c","pub_time":1743083400000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"截至2024年12月31日止年度年度业绩公告；非执行董事辞任；及建议修订组织章程细则","symbol":"02410","title":"截至2024年12月31日止年度年度业绩公告；非执行董事辞任；及建议修订组织章程细则","titleType":"年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0327/2025032702334_c.pdf","us_notice_code":"公告及通告 - [末期业绩 / 暂停办理过户登记手续或更改暂停办理过户日期 / 更换董事或重要行政职能或职责的变更 / 修...更多]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Annual Report","event_type":"important_notice","event_name":"年度报告","pubTime":"2025-03-27 21:50","pubTimestamp":1743083400,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"18653724","market":"hk","labels":[],"media":"港交所","original_id":"N.HKDa8ffoZeXZ","pdf_url":"https://static.tigerbbs.com/3bf20bbd552f4fde9768a429aa07ab21","pub_time":1727426700000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"2024中期报告","symbol":"02410","title":"2024中期报告","titleType":"半年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2024/0927/2024092700920_c.pdf","us_notice_code":"财务报表/环境、社会及管治资料 - [中期/半年度报告]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Interim Report","event_type":"important_notice","event_name":"半年度报告","pubTime":"2024-09-27 16:45","pubTimestamp":1727426700,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"18559041","market":"hk","labels":[],"media":"港交所","original_id":"N.HKJ6zpjRgpMT","pdf_url":"https://static.tigerbbs.com/be1fa360987748aa9d1e9642550fe2d3","pub_time":1725007620000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"截至2024年6月30日止六个月中期业绩公告","symbol":"02410","title":"截至2024年6月30日止六个月中期业绩公告","titleType":"半年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2024/0830/2024083000942_c.pdf","us_notice_code":"公告及通告 - [中期业绩]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Interim Report","event_type":"important_notice","event_name":"半年度报告","pubTime":"2024-08-30 16:47","pubTimestamp":1725007620,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"18458575","market":"hk","labels":[],"media":"港交所","original_id":"N.HK8CzhcJraXG","pdf_url":"https://static.tigerbbs.com/52b2dfd43b1b4917960f378086db6cae","pub_time":1723414560000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"全球发售","symbol":"02410","title":"全球发售","titleType":"股份发售","type":"hkIPO","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2024/0812/2024081200006_c.pdf","us_notice_code":"上市文件 - [发售以供认购]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"上市文件","type_name_en":"Listing Document","titleTypeEn":"Shares Subscription","event_type":"important_notice","event_name":"股份发售","pubTime":"2024-08-12 06:16","pubTimestamp":1723414560,"notice_type":"","filling_tag":"","gpt_icon":0}],"currentPage":1,"bottom":true},"companyData":{"profile":{"stockEarnings":[{"period":"1week","weight":-0.1509},{"period":"1month","weight":-0.1462},{"period":"3month","weight":-0.1304},{"period":"6month","weight":-0.2577},{"period":"1year","weight":-0.6522},{"period":"ytd","weight":-0.1762}],"compareEarnings":[{"period":"1week","weight":-0.0309},{"period":"1month","weight":-0.0591},{"period":"3month","weight":0.0003},{"period":"6month","weight":0.0283},{"period":"1year","weight":0.12},{"period":"ytd","weight":0.0054}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"浙江同源康医药股份有限公司是一家致力于开发及商业化医药产品的中国公司。该公司专注于小分子药物开发，其主要产品包括TY-9591、TY-302和TY-2136。TY-9591是一种第三代EGFR-TKI，对EGFR突变具有抗肿瘤作用。TY-302是一种为治疗乳腺癌及前列腺癌等晚期实体瘤而开发的强效、选择性口服CDK4/6抑制剂。TY-2136b为自主研发、口服ROS1/NTRK抑制剂，用于治疗实体瘤。","exchange":"SEHK","name":"同源康医药-B","nameEN":"TYK MEDICINES-B"},"aProfile":null}}}